Mirum Pharmaceuticals, Inc. MIRM Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $521.31M+54.7% | $336.89M+80.8% | $186.37M+142% | $77.06M+303% | ||
| $181.18M+28.8% | $140.63M+37.1% | $102.61M-4.0% | $106.84M-18.7% | ||
| $257.03M+27.1% | $202.22M+38.6% | $145.88M+63.8% | $89.07M+50.4% | ||
| $543.45M+28.0% | $424.49M+43.6% | $295.53M+41.9% | $208.28M+8.2% | ||
| -$22.14M+74.7% | -$87.61M+19.7% | -$109.15M+16.8% | -$131.22M+24.3% | ||
| -4.2%+21.8pp | -26%+32.6pp | -58.6%+112pp | -170.3%+736pp | ||
| $14.39M+0.5% | $14.31M-5.3% | $15.11M-5.5% | $15.98M— | ||
| $2.59M+113% | $1.21M+143% | -$2.82M— | —— | ||
| -$21.43M+75.3% | -$86.91M+46.5% | -$162.42M-14.3% | -$142.07M— | ||
| $1.94M— | —— | $991K+115% | -$6.55M-17,792% | ||
| -$23.36M+73.4% | -$87.94M+46.2% | -$163.42M-20.5% | -$135.67M— | ||
| -4.5%+21.6pp | -26.1%+61.6pp | -87.7%+88.4pp | -176%— | ||
| -$0.49+73.5% | -$1.85+54.1% | -$4.03-0.2% | -$4.02— | ||
| $2.11M+103% | -$63.98M+34.9% | -$98.33M+23.2% | -$127.98M+25.9% | ||
| 0.4%+19.4pp | -19%+33.8pp | -52.8%+113pp | -166.1%+737pp | ||
| -$22.14M+74.7% | -$87.61M+19.7% | -$109.15M+16.8% | -$131.22M+24.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s revenue?
- Mirum Pharmaceuticals, Inc. (MIRM) generated $569.6M in revenue over the trailing twelve months, up 50.2% year over year.
- Is Mirum Pharmaceuticals, Inc. profitable?
- Mirum Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $798.8M over the trailing twelve months, a -140.2% net margin.
- What is Mirum Pharmaceuticals, Inc.'s earnings per share?
- Mirum Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-13.62.
- Where does Mirum Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
